Companies: 10,795·Total market cap: $144.5T
Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc

APUSAMEXHealthcare● Active
$1.13
$-0.15(-11.71%)
Market Cap$1421211
P/E Ratio—
52W High$40.31
52W Low$1.17
Overview

Apimeds Pharmaceuticals US, Inc (APUS) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001894525 · APUS · AMEX · as of Jun 9, 2026

Filing snapshot

118
Total Filings
10-Q
Latest Form
2026-05-26
Most Recent
2025
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001894525 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-05-04
Fiscal Year End
May 4, 2026
Accession No.
0001213900-26-051139
Primary Document
ea0288344-10k_apimeds.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001894525 · Accession 0001213900-26-051139

Latest Key Filings

10-QQuarterly Report
QUARTERLY REPORT
2026-05-26
View 10-Q on SEC
8-KCurrent Report
CURRENT REPORT
2026-05-05Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
10-QQuarterly Report
QUARTERLY REPORT
2026-05-26
View
NT 10-QNT 10-Q
NOTIFICATION OF LATE FILING
2026-05-15
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-05-07
View
8-KCurrent Report
CURRENT REPORT
2026-05-05
View
10-KAnnual Report
ANNUAL REPORT
2026-05-04
View
8-KCurrent Report
CURRENT REPORT
2026-05-04
View
8-KCurrent Report
FORM 8-K
2026-04-22
View
8-KCurrent Report
CURRENT REPORT
2026-04-16
View
425425
AMENDMENT NO. 1 TO FORM 8-K
2026-04-09
View
8-K/ACurrent Report (Amended)
AMENDMENT NO. 1 TO FORM 8-K
2026-04-09
View
NT 10-KNT 10-K
NOTIFICATION OF LATE FILING
2026-03-31
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-03-30
View
8-KCurrent Report
CURRENT REPORT
2026-03-26
View
8-KCurrent Report
CURRENT REPORT
2026-03-25
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-03-20
View
Showing 1–15 of 94 filingsForm 4 / 144 hidden· 118 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001894525  |  Exchange: AMEX · Healthcare

Apimeds Pharmaceuticals US, Inc (AMEX: APUS) has submitted 118 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2025. As a Healthcare sector company with CIK 0001894525, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Apimeds Pharmaceuticals US, Inc's most comprehensive regulatory disclosure. The most recent Apimeds Pharmaceuticals US, Inc 10-K was filed on 2026-05-04 for fiscal year ending 2026. Historical APUS 10-K annual reports are available from 2024 through 2026.

Investors researching Apimeds Pharmaceuticals US, Inc SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
QTTB SEC Filings →ANTX SEC Filings →MYO SEC Filings →POCI SEC Filings →MIRA SEC Filings →MLSS SEC Filings →IGC SEC Filings →SCYX SEC Filings →
→ APUS Financials→ APUS Earnings→ APUS Insider Trades

Frequently Asked Questions

APUS SEC Filings · 8 questions

Apimeds Pharmaceuticals US, Inc (APUS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 118 filings and access original documents at no cost. Apimeds Pharmaceuticals US, Inc's CIK is 0001894525.

APUS SEC filingsApimeds Pharmaceuticals US, Inc SEC documentsfind APUS 10-K